FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2280763514> ?p ?o ?g. }

• W2280763514 endingPage "110" @default.
• W2280763514 startingPage "104" @default.
• W2280763514 abstract "Background Whole-gland salvage Iodine-125-brachytherapy is a potentially curative treatment strategy for localised prostate cancer (PCa) recurrences after radiotherapy. Prognostic factors influencing PCa-specific and overall survival (PCaSS & OS) are not known. The objective of this study was to develop a multivariable, internally validated prognostic model for survival after whole-gland salvage I-125-brachytherapy. Materials and methods Whole-gland salvage I-125-brachytherapy patients treated in the Netherlands from 1993-2010 were included. Eligible patients had a transrectal ultrasound-guided biopsy-confirmed localised recurrence after biochemical failure (clinical judgement, ASTRO or Phoenix-definition). Recurrences were assessed clinically and with CT and/or MRI. Metastases were excluded using CT/MRI and technetium-99m scintigraphy. Multivariable Cox-regression was used to assess the predictive value of clinical characteristics in relation to PCa-specific and overall mortality. PCa-specific mortality was defined as patients dying with distant metastases present. Missing data were handled using multiple imputation (20 imputed sets). Internal validation was performed and the C-statistic calculated. Calibration plots were created to visually assess the goodness-of-fit of the final model. Optimism-corrected survival proportions were calculated. All analyses were performed according to the TRIPOD statement. Results Median total follow-up was 78 months (range 5–139). A total of 62 patients were treated, of which 28 (45%) died from PCa after mean (±SD) 82 (±36) months. Overall, 36 patients (58%) patients died after mean 84 (±40) months. PSA doubling time (PSADT) remained a predictive factor for both types of mortality (PCa-specific and overall): corrected hazard ratio’s (HR’s) 0.92 (95% CI: 0.86–0.98, p = 0.02) and 0.94 (95% CI: 0.90–0.99, p = 0.01), respectively (C-statistics 0.71 and 0.69, respectively). Calibration was accurate up to 96 month follow-up. Over 80% of patients can survive 8 years if PSADT > 24 months (PCaSS) and >33 months (OS). Only approximately 50% survival is achieved with a PSADT of 12 months. Conclusion A PSADT of respectively >24 months and >33 months can result in >80% probability of PCa- specific and overall survival 8 years after whole-gland salvage I-125-brachytherapy. Survival should be weighed against toxicity from a salvage procedure. Larger series and external validation are necessary." @default.
• W2280763514 created "2016-06-24" @default.
• W2280763514 creator A5003334099 @default.
• W2280763514 creator A5008243215 @default.
• W2280763514 creator A5008487332 @default.
• W2280763514 creator A5011656436 @default.
• W2280763514 creator A5015748331 @default.
• W2280763514 creator A5017996394 @default.
• W2280763514 creator A5021876584 @default.
• W2280763514 creator A5023031772 @default.
• W2280763514 creator A5024165425 @default.
• W2280763514 creator A5039957828 @default.
• W2280763514 creator A5046428223 @default.
• W2280763514 creator A5046463414 @default.
• W2280763514 creator A5072340345 @default.
• W2280763514 creator A5083172675 @default.
• W2280763514 date "2016-04-01" @default.
• W2280763514 modified "2023-09-26" @default.
• W2280763514 title "Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy" @default.
• W2280763514 cites W1969963974 @default.
• W2280763514 cites W1993064858 @default.
• W2280763514 cites W1993990219 @default.
• W2280763514 cites W1994682257 @default.
• W2280763514 cites W2023186552 @default.
• W2280763514 cites W2026270547 @default.
• W2280763514 cites W2028561887 @default.
• W2280763514 cites W2033276673 @default.
• W2280763514 cites W2041543289 @default.
• W2280763514 cites W2052927854 @default.
• W2280763514 cites W2065974896 @default.
• W2280763514 cites W2074550002 @default.
• W2280763514 cites W2079269528 @default.
• W2280763514 cites W2081924580 @default.
• W2280763514 cites W2087046046 @default.
• W2280763514 cites W2095521441 @default.
• W2280763514 cites W2095963917 @default.
• W2280763514 cites W2105318466 @default.
• W2280763514 cites W2108773718 @default.
• W2280763514 cites W2129925362 @default.
• W2280763514 cites W2136954385 @default.
• W2280763514 cites W2137611824 @default.
• W2280763514 cites W2138304857 @default.
• W2280763514 cites W2139529407 @default.
• W2280763514 cites W2148659017 @default.
• W2280763514 cites W2153515948 @default.
• W2280763514 cites W2169102736 @default.
• W2280763514 doi "https://doi.org/10.1016/j.radonc.2016.02.002" @default.
• W2280763514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26897512" @default.
• W2280763514 hasPublicationYear "2016" @default.
• W2280763514 type Work @default.
• W2280763514 sameAs 2280763514 @default.
• W2280763514 citedByCount "10" @default.
• W2280763514 countsByYear W22807635142017 @default.
• W2280763514 countsByYear W22807635142018 @default.
• W2280763514 countsByYear W22807635142019 @default.
• W2280763514 countsByYear W22807635142020 @default.
• W2280763514 countsByYear W22807635142021 @default.
• W2280763514 crossrefType "journal-article" @default.
• W2280763514 hasAuthorship W2280763514A5003334099 @default.
• W2280763514 hasAuthorship W2280763514A5008243215 @default.
• W2280763514 hasAuthorship W2280763514A5008487332 @default.
• W2280763514 hasAuthorship W2280763514A5011656436 @default.
• W2280763514 hasAuthorship W2280763514A5015748331 @default.
• W2280763514 hasAuthorship W2280763514A5017996394 @default.
• W2280763514 hasAuthorship W2280763514A5021876584 @default.
• W2280763514 hasAuthorship W2280763514A5023031772 @default.
• W2280763514 hasAuthorship W2280763514A5024165425 @default.
• W2280763514 hasAuthorship W2280763514A5039957828 @default.
• W2280763514 hasAuthorship W2280763514A5046428223 @default.
• W2280763514 hasAuthorship W2280763514A5046463414 @default.
• W2280763514 hasAuthorship W2280763514A5072340345 @default.
• W2280763514 hasAuthorship W2280763514A5083172675 @default.
• W2280763514 hasBestOaLocation W22807635142 @default.
• W2280763514 hasConcept C121608353 @default.
• W2280763514 hasConcept C126322002 @default.
• W2280763514 hasConcept C126838900 @default.
• W2280763514 hasConcept C126894567 @default.
• W2280763514 hasConcept C143998085 @default.
• W2280763514 hasConcept C2777008409 @default.
• W2280763514 hasConcept C2777416452 @default.
• W2280763514 hasConcept C2779466945 @default.
• W2280763514 hasConcept C2780192828 @default.
• W2280763514 hasConcept C2989005 @default.
• W2280763514 hasConcept C50382708 @default.
• W2280763514 hasConcept C509974204 @default.
• W2280763514 hasConcept C71924100 @default.
• W2280763514 hasConceptScore W2280763514C121608353 @default.
• W2280763514 hasConceptScore W2280763514C126322002 @default.
• W2280763514 hasConceptScore W2280763514C126838900 @default.
• W2280763514 hasConceptScore W2280763514C126894567 @default.
• W2280763514 hasConceptScore W2280763514C143998085 @default.
• W2280763514 hasConceptScore W2280763514C2777008409 @default.
• W2280763514 hasConceptScore W2280763514C2777416452 @default.
• W2280763514 hasConceptScore W2280763514C2779466945 @default.
• W2280763514 hasConceptScore W2280763514C2780192828 @default.
• W2280763514 hasConceptScore W2280763514C2989005 @default.
• W2280763514 hasConceptScore W2280763514C50382708 @default.
• W2280763514 hasConceptScore W2280763514C509974204 @default.

• next